Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries, and Roche today announced that they have entered into a worldwide discovery chemistry agreement.
 
Evotec OAI and Roche have a long-standing relationship that includes three chemistry alliances since 2001 when Evotec OAI began supporting four Roche sites in the design and synthesis of high quality chemical compounds. These compounds were added to the Roche compound library collection and used in their screening programmes. In 2003, the partnership was broadened in to a medicinal chemistry agreement.
 
Bernard Questier, Chief Business Officer of Evotec OAI, said: "The successful working relationship with Roche over the past three years has qualified Evotec OAI as a truly reliable partner. We are delighted that our track record in drug discovery solutions for Roche has resulted in the expansion of our partnership."
 
About Evotec OAI AG
Evotec OAI has established itself as the partner of choice for drug discovery and development solutions for pharmaceutical and biotechnology companies worldwide, maintaining its leadership role through innovation and unmatched customer service.
The Company's business strategy is clearly focussed on drug discovery. It has established the most comprehensive technology platform and skills that integrate its world-class biology and chemistry capabilities. Evotec OAI leverages this discovery engine in providing assay development and screening through to compound optimisation and drug manufacturing services to a broad and well-established network of customers. In addition, the Company engages in selected discovery programmes itself to develop drug candidates for early out-licensing. Evotec OAI's instrument and technology business is now successfully handled by its affiliate, Evotec Technologies.
With over 600 people in Hamburg, Germany and Oxfordshire, UK, Evotec OAI is dedicated to returning value to its shareholders and employees through a sustainable business strategy that balances short-term and long-term revenue opportunities.
www.evotecoai.com
 
Contact: Anne Hennecke, Investor Relations & Corporate Communications, Evotec OAI AG, Phone: +49-40-56081-286, anne.hennecke@evotecoai.com

Contact: Anne Hennecke, Investor Relations & Corporate Communications, Evotec OAI AG, Phone: +49-40-56081-286, anne.hennecke@evotecoai.com